HSP90AA1 and neoplasm: Hsp90 proteins from tumor cells are about 100-fold more potent in binding to its inhibitor 17-alllylaminogeldanamycin (17-AAG) than those from normal cells [36], indicating a potential of Hsp90 inhibitors in cancer therapy [37, 38].